Institute of science, Nirma University, Sarkhej Gandhinagar Highway, Ahmedabad
And
Directorate of research & Innovation, Nirma University, S.G. highway, Ahmedabad.
Specialisation
Cancer , Molecular Biology , Clinical research , Cancer biomarkers
About
Dr Heena Dave is presently working as Assistant Research Scientist in the Institute of Science, Nirma University. In addition to that, she is also serving Directorate of Research and Innovation, Nirma University. Dr Dave is a Bachelor of Science in Biochemistry from St Xavier?s College, Ahmedabad, Gujarat (1994), and Master of Science in Life Sciences from School of Sciences, Gujarat University. She earned her doctorate in Life Sciences from the Gujarat Cancer and Research Institute (GCRI) and Gujarat University. Moreover, Dr Dave was also awarded a Post-doctoral Fellowship in Cancer Research at NYU Langone Medical Center, New York (2012-2013). She has also earned a Post Graduate Diploma in Hospital and Healthcare from Ahmedabad Management Association and California University (2015). Dr Dave was associated with The Gujarat Cancer and Research Institute, Ahmedabad from August 1996 to June 2012 in various capacities from Junior Research Fellow, Junior Research Assistant, Research Assistant to Research Associate. Dr Dave was also associated with Institute of Science, Nirma University from 2013 to 2017 as Assistant Professor. Dr Dave is a recipient of the world?s most prestigious ?Fulbright-Nehru Doctoral and Professional Research Scholarship? during 2009-2010 awarded by United States-India Educational Foundation (USIEF). She is also an awardee of ?Benjamin DuranTravel Grant? award by Fulbright commission for her paper presented at American Association of Cancer Research Annual Meeting 2010; Washington DC, USA. Moreover, she has more than 6research awards; to name a few, ?Sitaram Joglekar Award? (2001), ?Professor A. R. RaoMemorial Young Researcher/Scientist Award? (2011) for her outstanding research contribution. Her research interest is in identifying cancer biomarkers and understanding their signaling pathways for prognosis and metastasis to select the treatment modalities leading to personalized therapy.
